Legend Capital, an independent venture capital firm, led a $107m Series E round in MicuRx Pharmaceuticals, which discovers and develops novel antibiotics to combat drug-resistant bacterial infections. MicuRx attracted a slew of investors including China Merchants Securities, Korea Investment Partners, Yingke PE, Founder H Fund, Zhongtai Ventures, and Detong Capital. The fresh proceeds will be used for new drug development, global clinical trials, pipeline advancement and drug commercialization in China.